Drug combination assays using Caenorhabditis elegans as a model system

被引:2
|
作者
Hernando, Guillermina [1 ]
Bouzat, Cecilia [1 ]
机构
[1] Univ Nacl Sur UNS, Dept Biol Bioquim & Farm, Inst Invest Bioquim Bahia Blanca, CONICET, RA-8000 Bahia Blanca, Argentina
关键词
Drug combination; Synergistic effect; Nematode; Anthelmintic drug; Drug resistance; Locomotion assays; Pharmacological treatments; Thymol; Levamisole; DISCOVERY;
D O I
10.1016/j.vascn.2025.107583
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The C. elegans drug combination assay evaluates the effects of drug combinations in the nematode Caenorhabditis elegans, serving as a valuable tool to assess the efficacy of pharmaceutical agents and natural compounds. Using C. elegans as a model organism, this method allows for the efficient screening of the combined effects of different drugs and evaluation of synergistic effects in drug combinations, which reduces the risk of developing drug resistance. Combination therapy, involving commercial drugs, new agents, or natural products, broadens treatment effectiveness by targeting multiple pathways, effectively managing complex diseases with minimized side effects. The method focuses on discovering effective drug combinations, such as anthelmintic drugs, streamlining earlystage drug discovery to save time and resources. Additionally, its versatility allows for application across most areas of pharmacology and toxicology, extending its usefulness beyond anthelmintic treatments. In the experiments, synchronized worms are exposed to different drug concentrations to evaluate behavioral changes, mostly alterations in worm locomotion. Concentration-response curves for changes in behavior are generated and EC50 or IC50 values determined for the individual drugs. To determine whether the effects of a drug combination are synergistic, additive, or antagonistic, at least three different concentration ratios must be tested. These combinations are then analyzed using specialized drug combination analysis software. This methodology ensures consistent and precise outcomes and evaluates drug impacts on worm behavior parameters crucial for effective pharmacological activity. In conclusion, the C. elegans drug combination assay provides critical insights for developing successful market formulations applicable across a wide range of pharmacological treatments. Its ability to efficiently screen for synergistic, additive, or antagonistic effects makes it a valuable tool for identifying effective therapeutic strategies, potentially reducing drug resistance and improving treatment outcomes in various medical and toxicological fields.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Survival assays using Caenorhabditis elegans
    Park, Hae-Eun H.
    Jung, Yoonji
    Lee, Seung-Jae V.
    MOLECULES AND CELLS, 2017, 40 (02) : 90 - 99
  • [2] In vivo Toxicity Evaluation of a Nano-drug Delivery System Using a Caenorhabditis elegans Model System
    Han Wenzhao
    Li Hui
    Yu Xiaoxuan
    Ke Junfeng
    Guo Feng
    Wang Liping
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2022, 38 (04) : 1018 - 1024
  • [3] In vivo Toxicity Evaluation of a Nano-drug Delivery System Using a Caenorhabditis elegans Model System
    Wenzhao Han
    Hui Li
    Xiaoxuan Yu
    Junfeng Ke
    Feng Guo
    Liping Wang
    Chemical Research in Chinese Universities, 2022, 38 : 1018 - 1024
  • [4] Caenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial Toxicity
    de Boer, Richard
    Smith, Ruben L.
    De Vos, Winnok H.
    Manders, Erik M. M.
    Brul, Stanley
    van der Spek, Hans
    PLOS ONE, 2015, 10 (05):
  • [5] A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease
    Kensuke Ikenaka
    Yuki Tsukada
    Andrew C. Giles
    Tadamasa Arai
    Yasuhito Nakadera
    Shunji Nakano
    Kaori Kawai
    Hideki Mochizuki
    Masahisa Katsuno
    Gen Sobue
    Ikue Mori
    Scientific Reports, 9
  • [6] Using Caenorhabditis elegans for antimicrobial drug discovery
    Desalermos, Athanasios
    Muhammed, Maged
    Glavis-Bloom, Justin
    Mylonakis, Eleftherios
    EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (06) : 645 - 652
  • [7] A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease
    IKenaka, Kensuke
    Tsukada, Yuki
    Giles, Andrew C.
    Arai, Tadamasa
    Nakadera, Yasuhito
    Nakano, Shunji
    Kawai, Kaori
    Mochizuki, Hideki
    Katsuno, Masahisa
    Sobue, Gen
    Mori, Ikue
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [8] A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans
    Burns A.R.
    Wallace I.M.
    Wildenhain J.
    Tyers M.
    Giaever G.
    Bader G.D.
    Nislow C.
    Cutler S.R.
    Roy P.J.
    Nature Chemical Biology, 2010, 6 (7) : 549 - 557
  • [9] Functional genomic approaches using the nematode Caenorhabditis elegans as a model system
    Lee, J
    Nam, S
    Hwang, SB
    Hong, MG
    Kwon, JY
    Joeng, KS
    Im, SH
    Shim, JW
    Park, MC
    JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 37 (01): : 107 - 113
  • [10] A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans
    Burns, Andrew R.
    Wallace, Iain M.
    Wildenhain, Jan
    Tyers, Mike
    Giaever, Guri
    Bader, Gary D.
    Nislow, Corey
    Cutler, Sean R.
    Roy, Peter J.
    NATURE CHEMICAL BIOLOGY, 2010, 6 (07) : 549 - 557